Xenetic Biosciences, Inc.
XBIO
$4.11
-$0.17-3.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 660.60K | 806.90K | 766.30K | 1.03M | 589.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 660.60K | 806.90K | 766.30K | 1.03M | 589.90K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 660.60K | 806.90K | 766.30K | 1.03M | 589.90K |
| SG&A Expenses | 1.08M | 647.60K | 615.90K | 815.20K | 657.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.63M | 1.31M | 1.39M | 1.57M | 1.31M |
| Operating Income | -971.70K | -502.10K | -623.00K | -544.70K | -724.40K |
| Income Before Tax | -929.70K | -456.40K | -579.10K | -509.90K | -688.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -929.70K | -456.40K | -579.10K | -509.90K | -688.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -929.70K | -456.40K | -579.10K | -509.90K | -688.70K |
| EBIT | -971.70K | -502.10K | -623.00K | -544.70K | -724.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.41 | -0.20 | -0.27 | -0.33 | -0.45 |
| Normalized Basic EPS | -0.25 | -0.12 | -0.17 | -0.21 | -0.28 |
| EPS Diluted | -0.41 | -0.20 | -0.27 | -0.33 | -0.45 |
| Normalized Diluted EPS | -0.25 | -0.12 | -0.17 | -0.21 | -0.28 |
| Average Basic Shares Outstanding | 2.29M | 2.29M | 2.18M | 1.54M | 1.54M |
| Average Diluted Shares Outstanding | 2.29M | 2.29M | 2.18M | 1.54M | 1.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |